In this Pharmaceutical Executive video interview, Panna Sharma, CEO, Lantern Pharma, explains with specific endpoints they'll be looking at in the Phase I trial to assess LP-284's potential efficacy a ...

PE: What are some of the unique challenges that CGT developers need to plan for and overcome when building their channel strategy? Lattanzi: Channel strategy is probably one of the most important ...

A Harvard Business School Healthcare Alumni Association Q&A with Dorie Clark, Instructor of Executive Education at the Columbia Business School.

From recruiting clinical trial participants, to engaging patients with their permission at the point of care, to creating brand lift and awareness, the marketing landscape for pharma presents both ...